Categories: News

Captario SUMTM, the leading life sciences data analytics platform, has been selected by Alnylam Pharmaceuticals to help optimize their portfolio management processes

GOTHENBURG, Sweden, Jan. 11, 2022 /PRNewswire-PRWeb/ — Captario, a Gothenburg-based life sciences decision analytics SaaS platform & services company, has been chosen by Alnylam Pharmaceuticals, a global biopharmaceutical company based in Cambridge, MA, to support their digital transformation journey of optimizing strategic project and portfolio forecasting and modeling. Focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics for genetically-defined diseases, Alnylam looks to manage the complexities of drug development with real-time dynamic modeling and data analytics through use of Captario SUM®.

Peter Ray, Alnylam’s VP Strategy & Portfolio Analytics, is pleased to be adopting Captario’s disruptive technology saying, “we are always looking for new innovations to streamline our decision-making processes and improve our business. This partnership extends the boundaries of current forecasting and valuation methods and enhances transparency and scalability, generating greater portfolio and project insight with less effort.”

“I’m very excited Alnylam has chosen Captario as their preferred long-term collaborative partner for strategic portfolio management” says Johannes Vänngård, CEO of Captario. “It is with great pleasure that we embark on this journey together with Alnylam, and I feel confident that Captario will transcend what is possible to achieve with a portfolio management system.”

For more information, contact Captario at team@captario.com.

About Captario
Captario AB combines decades of experience within the pharmaceutical industry and their proprietary SaaS-based decision analytics platform for individual assets and asset portfolios to make a positive step-change in strategic decision-making within pharma. The platform, Captario SUM® (Strategic Uncertainty Management), provides real-time answers and the ability to compare a vast magnitude of options based on visual modeling, workflow reporting, cloud-based simulation, and advanced AI-driven analytics, all gathered into one seamless solution.
http://www.captario.com

Media Contact

Oscar Hanson, Captario, 46 0705539980, oscar.hanson@captario.com

 

SOURCE Captario

Staff

Recent Posts

Angle PLC Announces Parsortix at European Breast Cancer Conference

PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCEANGLE presenting two…

2 hours ago

MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today…

5 hours ago

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY )…

5 hours ago

Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext…

5 hours ago

Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024

LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally…

14 hours ago

Free Dementia Training in Alabama

Bring Dementia Education at No Cost to Your Skilled Nursing HomeTUSCALOOSA, AL / ACCESSWIRE /…

14 hours ago